Get started

Fundamental Analysis

DHANUKA Price ActionAs of July 29, 2025, Dhanuka Agritech is trading near ₹1,845 after a strong upward move in today’s session. The stock is rebounding from recent consolidations and is now about 4% below its 52-week high of ₹1,925.80. Market capitalization stands around ₹7,900 crore, placing the company among the prominent players in the agrochemicals sector. Recent quarterly results indicated a 20% year-on-year rise in net sales, signaling robust business momentum. The company demonstrates strong returns on capital employed (over 27%) and keeps debt levels very low, maintaining a healthy balance sheet. Current valuation metrics show a price-to-earnings ratio between 19 and 28, and price-to-book is just over 4, reflecting premium quality and consistent profitability. Dhanuka’s return to near-highs is supported by renewed sector demand and stable earnings growth. Trading volume remains healthy, with the stock outpacing sector peers in terms of recent percentage gains. Near-term technicals favor continuation of the uptrend, though its premium valuation and proximity to resistance levels may mean volatility if overall market sentiment shifts. Dhanuka Agritech is well suited to investors seeking a leading name in Indian agrochemicals with a record of steady performance and balance sheet strength.
NSE:DHANUKALong
by KamalKJoshi
Narayana Hrudayalaya Ltd Price ActionNarayana Hrudayalaya Ltd (NH) is trading around ₹1,946 as of August 1, 2025, after hitting a record high of ₹2,370 in late June. The stock has gained over 53% in the past year and about 44% in the last six months, showing strong long-term momentum, though it has corrected nearly 10% over the previous month and 2% in the past week. Financially, NH remains robust. For the trailing twelve months, revenue stands at approximately ₹5,483 crore and net profit at ₹791 crore, giving a net profit margin of about 14.4%. The company’s market capitalization is close to ₹39,900 crore, making it one of the largest listed hospital operators in India. Key financial ratios include a price-to-earnings (P/E) ratio of about 49.5 and a price-to-book (P/B) ratio nearing 18—both substantially above the sector average, reflecting strong premium and optimistic growth expectations. Operating performance continues to impress: sales growth for the March quarter was up 15% year-on-year, while margins are stable and efficient. The most recent dividend declared is ₹4.50 per share, maintaining a rising payout trend. Technically, momentum is slightly negative in the short term, with bearish signals on daily moving averages and a recent drop below key short-term exponential averages, suggesting the possibility of near-term consolidation or mild pullback after a strong prior rally. In summary, NH remains a growth leader in the hospital and healthcare space, combining strong recent price performance and operational strength. The stock is trading at a substantial premium, justified by consistent growth and sector leadership, but near-term upside may be limited as the price consolidates from recent highs and digest valuation multiples, especially if no further earnings acceleration materializes.
NSE:NHLong
by KamalKJoshi
Hester Price ActionAs of July 31, 2025, Hester Biosciences Ltd is trading near ₹1,950 after a recent rebound, though it has experienced a significant decline over the past year, down roughly 37% from its 52-week high above ₹3,250. The stock’s recovery in the last three months has been moderate, with gains of about 9%, and short-term sentiment appears slightly positive given the recent upward movement. The company’s current price-to-earnings ratio is elevated, close to 58, and the price-to-book ratio is about 4.9, indicating a premium valuation compared to its book value. Hester Biosciences maintains a market capitalization near ₹1,650 crore, placing it among smaller specialty pharma and agri-biotech firms. While the core fundamentals show resilience, the firm recently reported a contraction in sales for the first time in three years, which led to some investor caution. Technically, Hester Biosciences is recovering from its yearly lows near ₹1,240 and is showing renewed buying interest at current levels, confirmed by an uptick in volumes and momentum. However, given the sharply reduced returns over the past year, sentiment is mixed, and further upside will likely depend on improvement in financial result trends and any breakout above resistance points established during its downtrend. Overall, the near-term outlook is cautiously constructive with recent stabilization, but investors should monitor for sustained improvements in revenue and earnings to confirm a continued reversal.
NSE:HESTERBIOLong
by KamalKJoshi
RHIM Price ActionRHI Magnesita India Ltd (RHIM) is trading around ₹529 in early August 2025, having shown notable volatility over the past several months. The stock has ranged between a recent low of about ₹503 and a high near ₹538 in the last few days. The annual performance indicates a mild decline over the last year but double-digit gains in the last three to six months, pointing to a marked recovery from earlier lows. Financially, RHIM carries a relatively high valuation, with a price-to-earnings ratio close to 54 and a price-to-book value of about 2.8. Operating fundamentals are decent but not exceptional: return on equity remains moderate, and promoter holdings have slightly decreased over the past few years. The company offers a modest dividend yield of about 0.5%, providing limited income support to investors. In terms of recent momentum, trading volumes have spiked, indicating renewed interest, and short-term technicals suggest the possibility of continued oscillation within the current price band. The stock’s long-term prospects remain tied to trends in the refractories and industrial materials sector, where growth has been consistent but not rapid. In summary, RHIM is exhibiting renewed price momentum but continues to trade at elevated valuation multiples. The company’s stable position in its sector and improving sentiment support the stock at current levels, though further substantial upside will likely depend on sustained earnings growth and sector expansion.
NSE:RHIMLong
by KamalKJoshi
HARSHA Price ActionHarsha Engineers International Ltd is trading around ₹414 as of early August 2025. The stock has seen a modest increase of about 3% over the past six months but a significant decline of roughly 23% over the past year. The 52-week price range is wide, with a low near ₹330 and a high close to ₹584, indicating notable price volatility. Valuation-wise, the stock trades at a price-to-earnings ratio around 35 and a price-to-book ratio near 0.33 to 3.1 depending on sources, reflecting mixed signals; the low book value multiple might suggest undervaluation relative to its assets, while the P/E suggests reasonable earnings expectations. The company has a market capitalization near ₹3,770 crore. Financially, Harsha Engineers has delivered poor sales growth of under 10% over the past five years, which may have contributed to the recent price softness. Dividend announcements have been made recently, providing some income to shareholders. The stock’s mid-term outlook appears cautious with moderate price movement and valuation reflecting both risks from muted growth and some stability in fundamentals. In summary, Harsha Engineers currently trades at a level indicating some undervaluation on a book value basis, but the stock price reflects concerns about slow growth and past volatility. Investors should weigh the company’s solid asset base against subdued sales growth and potential market fluctuations when considering the stock.
NSE:HARSHALong
by KamalKJoshi
Kajaria Ceramics Price ActionKajaria Ceramics is currently trading around ₹1,177, with a market capitalization close to ₹18,750 crore as of the end of July 2025. The stock has shown solid performance in recent months—up about 46% over the last quarter and nearly 19% in the past six months, although it experienced a mild 0.2% dip over the last week. Despite this rally, the stock is valued at a relatively high price-to-earnings (P/E) ratio of around 59 and a price-to-book (P/B) ratio of approximately 6.6, suggesting that it is trading at a premium to its asset base and compared to industry averages. Profit growth has lagged sales growth, with annual sales increasing modestly but profit growth remaining subdued. The 52-week price range is quite wide, with a high of ₹1,579 and a low of ₹759, reflecting periods of both volatility and strong recoveries. Analyst outlook remains moderately positive, with one-year price targets averaging near ₹1,259 but estimates ranging widely from ₹731 to ₹1,716. Near-term forecasts mostly see the price consolidating between ₹1,150–₹1,200, with oscillations rather than sustained moves upward or downward. In summary, Kajaria Ceramics stands out for its recent price momentum and market strength. However, its stretched valuation multiples and only moderate earnings growth highlight the need for careful consideration if expecting further near-term appreciation. The company's premium valuation is reliant on continued improvement in industry demand and profitability. Its financial position and recent run-up make it a stable but potentially fully valued pick at present levels.
NSE:KAJARIACERLong
by KamalKJoshi
TIINDIA Price ActionTata Investment Corporation Ltd (TIINDIA) is mainly an investment holding company, and its share price reflects both its portfolio performance and market sentiment. At present, the company maintains a very strong financial position with almost no debt, providing security for shareholders. Its stock is trading at a valuation close to its book value, suggesting a fair price relative to its underlying assets. However, the actual returns from TIINDIA’s own operations remain modest. Return on equity is low and profit growth has been muted in recent years, which indicates limited profitability from its core business. The company’s strong dividend history provides stable income to investors, but earnings growth remains subdued. Despite a substantial rise in the stock price over the past several years, more recent performance has slowed, aligning with weaker earnings growth. The high price-to-earnings ratio, when compared to its limited profit generation, implies that the stock may be fully valued or even expensive at current levels. Future upside for TIINDIA is likely to depend heavily on a significant rebound in the market value or profits of its investment portfolio. Overall, TIINDIA offers stability and low financial risk, but prospects for sharp appreciation are currently limited unless there’s a meaningful turnaround in its earnings or portfolio companies.
NSE:TIINDIALong
by KamalKJoshi
4
Route Mobile Bottomed-out for Highest UpsideMy Stock View and Opinion: Double-bottom pattern identified, Huge upside potential as enterprise communication continues to evolve globally. Strategic Moves: 1) Successful integration with global CPaaS major Kaleyra, unlocking access to 100+ countries and Tier-1 enterprise clients. 2) Backed by Proximus Group (Belgium), enhancing global reach and enterprise credibility. 3) Collaboration with Nokia to deliver secure, carrier-grade CPaaS services to telecom operators globally. Strong execution capabilities, strategic partnerships with global telecom leaders, scalable SaaS-driven model, and growing demand for digital engagement platforms position Route Mobile for sustained multi-year growth.
BSE:ROUTELong
by Jeevyog
Zuari Price ActionAs of July 24, 2025, Zuari Agro Chemicals Ltd is trading around ₹215 to ₹218 per share. The stock has shown a recent slight decline of about 1.27% on that day. Its market capitalization is approximately ₹900 crore, placing it among the mid-sized chemical and fertilizer companies. The 52-week price range for Zuari Agro Chemicals is between ₹169 and ₹268, reflecting moderate volatility over the past year. The stock is trading closer to the lower-middle part of this range, about 18–20% below its 52-week high. Fundamentally, the company demonstrates reasonable valuation metrics, with a price-to-earnings (P/E) ratio near 5.5, which is quite attractive compared to the sector average, and a price-to-book (P/B) ratio below 0.5, indicating it is trading at a significant discount to book value. Recent earnings per share show solid growth, contributing to strong profitability metrics. Operationally, Zuari Agro Chemicals continues to build stable revenues within the fertilizers segment, benefitting from sectoral demand and government policies supporting agriculture inputs. The company maintains average financial strength with ongoing measures to reduce debt and improve operational efficiency. On the technical front, the stock has experienced some consolidation after modest gains over recent months but remains vulnerable to market sentiment shifts in the commodity and fertilizer sectors. Overall, Zuari Agro Chemicals offers a fair valuation entry for investors seeking exposure to the fertilizer industry with moderate risk. The current price implies value relative to its historical range, supported by steady earnings, though the stock price is subject to volatility driven by agricultural commodity cycles and sector-specific factors.
NSE:ZUARILong
by KamalKJoshi
1
Swiggy Ltd. Reserch ReportBuy/Sell/Hold Recommendation: Given Swiggy’s strong revenue growth but continued losses and negative cash flows, the stock currently represents a high-risk, high-reward opportunity. Unless you have a high risk appetite and a long-term horizon, a "Hold" stance is appropriate—wait for visible margin improvement and positive cash flows before considering aggressive buying. For conservative investors, it’s best to avoid new buys until profitability and sustainable cash generation are in sight. Only enter or add if Swiggy shows concrete signs of turning profitable and scaling successfully. HOld (Overvalued) Swiggy Investment Report: Independent Strategic & Financial Outlook Introduction Swiggy, a leading player in India’s food delivery and quick commerce industry, continues to pursue aggressive growth and operational dominance, shaping its own strategic path amid sector challenges. Financial Metrics In FY25, Swiggy posted revenue of ₹15,227Cr but remained loss-making with a net deficit of ₹3,117Cr and negative EBITDA margins, reflecting heavy investment in technology, logistics, and expansion—especially in its Instamart quick commerce division. Capital expenditures and higher working capital are keeping free cash flows negative (-₹2,693Cr in FY25), underscoring the company’s high-growth, cash-consuming phase. Strategic Progress & DCF Valuation Swiggy’s management aims for positive cash flows and margin turnaround, with plans to steadily improve profitability by scaling operations and increasing efficiency. A detailed DCF analysis, based on realistic growth and margin improvement assumptions (cost of equity 11.79%, terminal growth 10%), implies an intrinsic value of around ₹143 per share—indicating the current market cap still prices in optimism about future execution. Key Takeaways Swiggy operates in a capital-intensive, competitive market, facing margin pressure but also strong revenue momentum. Ongoing board and policy reforms reflect the company’s drive for operational maturity. Long-term success hinges on rapid margin improvement, successful turnaround of Instamart, and conversion of scale into sustainable profits. Conclusion Swiggy’s independent outlook shows promise with its robust platform and growth potential, but significant risks remain until losses are narrowed and cash flows turn consistently positive. For investors, Swiggy presents a high-risk, high-reward bet—success will be determined by its pace of execution and ability to transition from investment-driven growth to profitable leadership in India’s booming delivery market.
NSE:SWIGGY
by Tap_trader
CAPLIPOINT Price ActionAs of July 31, 2025, Caplin Point Laboratories Ltd (CAPLIPOINT) is trading near ₹2,085, showing a mixed but steady performance with some recent price fluctuations around this level. The stock briefly touched intraday highs around ₹2,095 and lows near ₹2,030, maintaining support in the ₹2,030–₹2,055 range. Market capitalization stands broadly near ₹15,590 crore. Caplin Point benefits from solid fundamentals in the pharmaceutical sector, supported by consistent revenue growth and operational efficiencies. The price-to-earnings ratio sits around 29, while the price-to-book ratio is approximately 5.5, indicating premium valuation relative to book but in line with sector expectations. Dividend yield is low at about 0.15%, reflecting the company’s focus on growth over payout. Technically, the stock tends to hover above its medium-term moving averages like the 50-day and 200-day SMAs, showing cautious bullish momentum, although near-term volatility remains. Trading volumes are moderate, and the relative strength index is near mid-range levels, suggesting balanced momentum without overbought or oversold extremes. Overall, Caplin Point Laboratories currently reflects steady fundamentals with a valuation premium typical of its pharma peer group, supported by stable trading ranges and positive medium-term technical signals. The near-term outlook remains cautiously optimistic, with key support near ₹2,030 and potential resistance around ₹2,100–₹2,120.
NSE:CAPLIPOINTLong
by KamalKJoshi
Jubilant Price ActionAs of July 31, 2025, Jubilant Pharmova Ltd is trading around ₹1,236, showing strong bullish momentum with gains of over 7% in recent sessions. The stock has recovered well from lower levels near ₹1,170 seen earlier, with sustained buyer interest and solid volume support. Technical indicators reveal that the price is above its short-term moving averages, reflecting positive market sentiment. Fundamentally, Jubilant Pharmova maintains a robust position in the pharmaceutical and life sciences sector with steady revenue growth and improving profitability. The company benefits from a diversified business model and ongoing operational efficiencies, which have helped it sustain earnings growth amid industry challenges. Valuation metrics like the price-to-earnings ratio are moderate, reflecting reasonable investor confidence relative to sector peers. The near-term outlook for Jubilant Pharmova appears constructive, with potential for further upside provided it holds above key support levels around ₹1,170–₹1,180. Momentum indicators and volume trends support the continuation of the uptrend, although investors should remain cautious of profit-booking risks after sharp rallies. In summary, Jubilant Pharmova demonstrates solid fundamental strength and positive technical signs, making it an appealing choice for investors seeking exposure to the pharmaceutical sector with a growth orientation.
NSE:JUBLPHARMALong
by KamalKJoshi
Refex Price ActionAs of July 31, 2025, Refex Industries is trading near ₹448, showing strong bullish momentum with recent gains of about 10% in the last day. The stock has held well above key support levels near ₹400–₹430, indicating solid buyer interest. It has a market capitalization close to ₹5,800 crore. Fundamentally, Refex Industries carries a price-to-earnings ratio around 33 and a price-to-book ratio above 4, which suggests a premium valuation supported by solid profitability—the return on equity stands near 30%. Technically, the stock trades above short- and medium-term moving averages such as the 5-day, 10-day, and 20-day SMAs, with some resistance expected around ₹450–₹465. Breaking above this level could open further upside potential toward ₹480–₹500. Volume trends in recent sessions confirm the strength of the price move, and the relative strength index (RSI) indicates room for further upside before becoming overbought. In summary, Refex Industries exhibits strong upward price action backed by healthy fundamentals and volume support. Key levels to watch include support near ₹400–₹430 and resistance at ₹450–₹465, with the near-term outlook remaining constructive on sustained momentum.
NSE:REFEXLong
by KamalKJoshi
NIACL Price ActionAs of July 30, 2025, New India Assurance Company Ltd (NIACL) stock closed near ₹204, showing a strong recovery with a sharp rally of around 17% in a single day fueled by robust Q1 earnings and positive market sentiment. The stock bounced back from earlier volatility and support levels near ₹170, with technicals indicating bullish momentum supported by moving average crossovers. NIACL’s recent financial performance has been impressive with an 80% surge in net profit year-on-year and a 13% growth in gross written premiums, reflecting strong industry position and operational gains. Its market capitalization stands near ₹33,676 crore with a price-to-earnings ratio around 32 and a price-to-book ratio about 1.2, suggesting valuation in line with sector averages but on the higher side. While the stock has faced some volatility and a one-year decline near 27%, it has gained nearly 19% over the past three months, driven by improved underwriting efficiency and investment income stability. Analysts remain cautiously optimistic about its near-term upside potential, assuming continued operational improvements and support at key price levels. In summary, NIACL currently presents a turnaround profile with renewed earnings strength, improving fundamentals, and constructive technical signals, making it an interesting candidate for medium-term investors willing to tolerate some volatility.
NSE:NIACLLong
by KamalKJoshi
EPIGRAL - BreakoutEpigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure. In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen. Breakout from the Triangle pattern Market Cap: ₹ 8,996 Cr. Promoter holding: 68.8 % FII holding: 3.06 % DII holding: 4.78 % Public holding: 23.3 % Debt: ₹ 593 Cr. Debt 3Years back: ₹ 993 Cr.
NSE:EPIGRALLong
by isagar_chauhan_
GVT&D Price ActionGE Vernova T&D India Ltd (GVT&D) has experienced a significant surge, with its stock price around ₹2,597 as of July 30, 2025. Over the past year, the stock delivered an impressive return of about 61%. Over three years, the returns are even more dramatic, exceeding 2,100%. However, the broader financials reveal a company with mixed metrics. The stock’s high price-to-earnings (P/E) ratio and price-to-book value suggest it is currently overvalued compared to peers and the market average. Analyst forecasts for the next 12 months range between ₹2,005 and ₹3,000, with a consensus target near ₹2,450. Most analysts continue to view the stock favorably and assign it a “strong buy” outlook, though with caution about its rich valuation. GVT&D’s profitability stands out; it has shown robust growth in both operating profit and earnings per share recently. Return on equity has climbed above 40% in the past year, indicating efficiency in generating returns for shareholders. The company is also almost debt-free and maintains stable cash flows, which reduces financial risk. Volatility for GVT&D is slightly higher than the market average, but price movement has been relatively stable, with no extreme swings in recent months. Still, investors should be aware that such high past returns may not be sustainable, especially with modest sales growth and valuation multiples well above industry norms. In summary, GVT&D remains a high-performing and highly-valued stock in the Indian power equipment sector, with strong recent momentum, robust profitability, and a largely positive market outlook—albeit with potential risk due to elevated pricing and slower sales growth compared to its historic surge.
NSE:GVT&DLong
by KamalKJoshi
Trump's broad policies to secure America's hegemony.Hello trader and an investor, Here, I am telling you about Trump's extensive policies that will secure America's dominance, but only in brief format. See below. 1. Unresolved Issues: * Economic overheating impact on US Hegemony. * Expansionary Fiscal policy sustained accumulation of Debt Burden. * Instability of Dollar & US Treasuries status , rising Threat from China. 2. policy Responses: * Fiscal policy: Tax cuts to stimulate economic growth and Expanded national defense spending. * Monetary policy: Rate cuts, End of balance sheet reduction. * Trade & External policy: Tariff revenue, Fiscal subsidies. * Regulatory Measures: stabilize banking sector and maintain US Treasury market loosen Supplementary Leverage Ratio (SLR). * Technological competition: Promote AI and infrastructure development, Revitalize nuclear energy. 3. Legislation & Government Actions: * One Big Beautiful Bill Act. * Nomination of new Fed chair. * Reciprocal tariffs & industrial tariffs. * GENIUS CLARITY. * AI initiative & nuclear revival plan. 4. Beneficiary sectors: * AI , Semiconductors, Defense. * Broad- based ( Tech, Agriculture, Manufacturing). * Blockchain & key technologies. * AI, Nuclear Energy
COMEX:GC1!Education
by manasiparulekar8
2
BUY TODAY SELL TOMORROW for 5%DON’T HAVE TIME TO MANAGE YOUR TRADES? - Take BTST trades at 3:25 pm every day - Try to exit by taking 4-7% profit of each trade - SL can also be maintained as closing below the low of the breakout candle Now, why do I prefer BTST over swing trades? The primary reason is that I have observed that 90% of the stocks give most of the movement in just 1-2 days and the rest of the time they either consolidate or fall Consolidation Breakout in MBAPL BUY TODAY SELL TOMORROW for 5%
NSE:MBAPL
by Kapil-Mittal
12